{"id":2755,"date":"2024-04-07T18:00:00","date_gmt":"2024-04-07T10:00:00","guid":{"rendered":"https:\/\/dianhuaminglu.com\/?p=2755"},"modified":"2024-04-08T14:48:08","modified_gmt":"2024-04-08T06:48:08","slug":"%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%82%be%e7%99%8c%e9%80%82%e5%ba%94%e7%97%87%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7%e6%89%b9","status":"publish","type":"post","link":"https:\/\/dianhuaminglu.com\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%82%be%e7%99%8c%e9%80%82%e5%ba%94%e7%97%87%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7%e6%89%b9\/","title":{"rendered":"\u541b\u5b9e\u751f\u7269\u5ba3\u5e03\u7279\u745e\u666e\u5229\u5355\u6297\u80be\u764c\u9002\u5e94\u75c7\u5728\u4e2d\u56fd\u83b7\u6279"},"content":{"rendered":"\n
\u5317\u4eac\u65f6\u95f42024\u5e744\u67087\u65e5\uff0c\u541b\u5b9e\u751f\u7269\uff081877.HK\uff0c688180.SH\uff09\u5ba3\u5e03\uff0c\u7531\u516c\u53f8\u81ea\u4e3b\u7814\u53d1\u7684\u6297PD-1\u5355\u6297\u836f\u7269\u7279\u745e\u666e\u5229\u5355\u6297\u6ce8\u5c04\u6db2\uff08\u62d3\u76ca\u00ae<\/sup>\uff09\u8054\u5408\u963f\u6614\u66ff\u5c3c\u7528\u4e8e\u4e2d\u9ad8\u5371\u7684\u4e0d\u53ef\u5207\u9664\u6216\u8f6c\u79fb\u6027\u80be\u7ec6\u80de\u764c\u60a3\u8005\u7684\u4e00\u7ebf\u6cbb\u7597<\/strong>\u65b0\u9002\u5e94\u75c7\u4e0a\u5e02\u7533\u8bf7\u4e8e\u8fd1\u65e5\u83b7\u5f97\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u6279\u51c6\u3002\u8fd9\u662f\u7279\u745e\u666e\u5229\u5355\u6297\u5728\u4e2d\u56fd\u83b7\u6279\u7684\u7b2c\u516b\u9879<\/strong>\u9002\u5e94\u75c7\uff0c\u4e5f\u662f\u6211\u56fd\u9996\u4e2a<\/strong>\u83b7\u6279\u7684\u80be\u764c\u514d\u75ab\u7597\u6cd5\u3002<\/p>\n\n\n\n \u80be\u764c\u662f\u5168\u7403\u6ccc\u5c3f\u7cfb\u7edf\u7b2c\u4e09\u4f4d\u6700\u5e38\u89c1\u7684\u6076\u6027\u80bf\u7624\uff0c\u800c\u80be\u7ec6\u80de\u764c\uff08RCC\uff09\u5360\u5168\u90e8\u80be\u764c\u75c5\u4f8b\u768480%~90%1<\/sup>\u3002\u636e\u7edf\u8ba1\uff0c2022\u5e74\u4e2d\u56fd\u80be\u764c\u65b0\u53d1\u75c5\u4f8b\u548c\u6b7b\u4ea1\u75c5\u4f8b\u5206\u522b\u7ea6\u4e3a7.7\u4e07\u4f8b\u548c4.6\u4e07\u4f8b2<\/sup>\u3002\u7ea6\u4e09\u5206\u4e4b\u4e00\u7684\u80be\u764c\u60a3\u8005\u5728\u521d\u8bca\u65f6\u5df2\u53d1\u751f\u80bf\u7624\u8fdc\u5904\u8f6c\u79fb\uff0c\u800c\u5c40\u9650\u6027\u60a3\u8005\u63a5\u53d7\u80be\u5207\u9664\u672f\u540e\u4ecd\u670920-50%\u51fa\u73b0\u80bf\u7624\u8fdc\u5904\u8f6c\u79fb3,4<\/sup>\u3002\u57fa\u4e8e\u56fd\u9645\u8f6c\u79fb\u6027\u80be\u7ec6\u80de\u764c\u6570\u636e\u5e93\u8054\u76df\u7684\u98ce\u9669\u5206\u7ea7\uff0c\u4f4e\u5371\u3001\u4e2d\u5371\u548c\u9ad8\u5371\u7684\u8f6c\u79fb\u6027RCC\u60a3\u8005\u63a5\u53d7\u6297\u8840\u7ba1\u9776\u5411\u6cbb\u7597\u7684\u4e2d\u4f4d\u603b\u751f\u5b58\u671f\uff08OS\uff09\u5206\u522b\u4e3a35.3\u300116.6\u548c5.4\u4e2a\u67081,5<\/sup>\u3002\u56e0\u6b64\uff0c\u76f8\u8f83\u4e8e\u4f4e\u5371\u60a3\u8005\uff0c\u4e2d\u3001\u9ad8\u5371\u665a\u671fRCC\u60a3\u8005\u5bf9\u65b0\u578b\u6cbb\u7597\u65b9\u6848\u7684\u4e34\u5e8a\u9700\u6c42\u66f4\u52a0\u8feb\u5207\u3002<\/p>\n\n\n\n \u6b64\u6b21\u65b0\u9002\u5e94\u75c7\u7684\u83b7\u6279\u4e3b\u8981\u57fa\u4e8eRENOTORCH\u7814\u7a76\uff08NCT04394975\uff09\u7684\u6570\u636e\u7ed3\u679c\u3002RENOTORCH\u7814\u7a76\u662f\u4e00\u9879\u591a\u4e2d\u5fc3\u3001\u968f\u673a\u3001\u5f00\u653e\u3001\u9633\u6027\u836f\u5bf9\u7167\u7684\u2162\u671f\u4e34\u5e8a\u7814\u7a76\uff0c\u7531\u5317\u4eac\u5927\u5b66\u80bf\u7624\u533b\u9662\u90ed\u519b\u6559\u6388<\/strong>\u548c\u4e0a\u6d77\u4ea4\u901a\u5927\u5b66\u533b\u5b66\u9662\u9644\u5c5e\u4ec1\u6d4e\u533b\u9662\u9ec4\u7ffc\u7136\u6559\u6388<\/strong>\u62c5\u4efb\u4e3b\u8981\u7814\u7a76\u8005\uff0c\u5728\u5168\u56fd47\u5bb6\u4e34\u5e8a\u4e2d\u5fc3\u5f00\u5c55\uff0c\u662f\u6211\u56fd\u9996\u4e2a\u665a\u671f\u80be\u764c\u514d\u75ab\u6cbb\u7597\u7684\u5173\u952e\u2162\u671f\u4e34\u5e8a\u7814\u7a76<\/strong>\u3002<\/p>\n\n\n\n \u8be5\u7814\u7a76\u5171\u968f\u673a\u5165\u7ec4421\u4f8b\u4e2d\u9ad8\u5371\u7684\u4e0d\u53ef\u5207\u9664\u6216\u8f6c\u79fb\u6027RCC\u60a3\u8005\uff0c\u4ee51:1\u968f\u673a\u5206\u914d\u81f3\u7279\u745e\u666e\u5229\u5355\u6297\u8054\u5408\u963f\u6614\u66ff\u5c3c\u7ec4\uff08n=210\uff09\u6216\u8212\u5c3c\u66ff\u5c3c\u7ec4\uff08n=211\uff09\u63a5\u53d7\u6cbb\u7597\u3002\u4e3b\u8981\u7814\u7a76\u7ec8\u70b9\u662f\u72ec\u7acb\u8bc4\u5ba1\u59d4\u5458\u4f1a\uff08IRC\uff09\u8bc4\u4f30\u7684\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\uff0c\u6b21\u8981\u7814\u7a76\u7ec8\u70b9\u5305\u62ec\u7814\u7a76\u8005\u8bc4\u4f30\u7684PFS\u3001IRC\u6216\u7814\u7a76\u8005\u8bc4\u4f30\u7684\u5ba2\u89c2\u7f13\u89e3\u7387\uff08ORR\uff09\u3001\u7f13\u89e3\u6301\u7eed\u65f6\u95f4\uff08DoR\uff09\u3001\u75be\u75c5\u63a7\u5236\u7387\uff08DCR\uff09\u3001\u603b\u751f\u5b58\u671f\uff08OS\uff09\u4ee5\u53ca\u5b89\u5168\u6027\u7b49\u3002<\/p>\n\n\n\n \u6b64\u524d\uff0cRENOTORCH\u7684\u7814\u7a76\u6210\u679c\u57282023\u5e74\u6b27\u6d32\u80bf\u7624\u5185\u79d1\u5b66\u4f1a\uff08ESMO\uff09\u5927\u4f1a\u4f18\u9009\u53e3\u5934\u62a5\u544a\u4e13\u573a\u4f1a\u8bae\u4e0a\u9996\u6b21\u53d1\u5e03\uff0c\u5168\u6587\u540c\u6b65\u83b7ESMO\u5b98\u65b9\u671f\u520a\u300a\u80bf\u7624\u5b66\u5e74\u9274\u300b\uff08Annals of Oncology<\/em>\uff1b\u5f71\u54cd\u56e0\u5b50\uff1a50.5\uff1b\u80bf\u7624\u9886\u57df\u5168\u7403\u6392\u540dTOP5\u7684\u9876\u7ea7\u671f\u520a\uff09\u53d1\u8868\u3002\u7814\u7a76\u6570\u636e\u663e\u793a\uff0c\u57fa\u4e8eIRC\u8bc4\u4f30\u7ed3\u679c\uff0c\u4e0e\u8212\u5c3c\u66ff\u5c3c\u5355\u836f\u6cbb\u7597\u76f8\u6bd4\uff0c\u63a5\u53d7\u7279\u745e\u666e\u5229\u5355\u6297\u8054\u5408\u963f\u6614\u66ff\u5c3c\u6cbb\u7597\u53ef\u663e\u8457\u5ef6\u957f\u60a3\u8005\u7684PFS\uff08\u4e2d\u4f4dPFS\uff1a18.0 vs. 9.8\u4e2a\u6708\uff0cP=0.0028\uff09\uff0c\u60a3\u8005PFS\u5ef6\u957f\u8fd12\u500d\uff0c\u75be\u75c5\u8fdb\u5c55\u6216\u6b7b\u4ea1\u98ce\u9669\u964d\u4f4e35%\uff08\u98ce\u9669\u6bd4[HR]=0.65\uff1b95%CI\uff1a0.49\uff0c0.86\uff09\u3002\u6b64\u5916\uff0c\u7279\u745e\u666e\u5229\u5355\u6297\u7ec4\u7684ORR\u66f4\u4f18\uff0856.7% vs. 30.8%\uff0cP<0.0001\uff09\uff0c\u5e76\u4e14DoR\u66f4\u957f\uff08\u4e2d\u4f4dDoR\uff1a\u672a\u8fbe\u5230 vs. 16.7\u4e2a\u6708\uff1bHR=0.61\uff09\uff0c\u5177\u6709\u660e\u663e\u7684OS\u83b7\u76ca\u8d8b\u52bf\uff08\u4e2d\u4f4dOS\uff1a\u672a\u8fbe\u5230 vs. 26.8\u4e2a\u6708\uff09\uff0c\u6b7b\u4ea1\u98ce\u9669\u964d\u4f4e39%\uff08HR=0.61\uff1b95%CI\uff1a0.40\uff0c0.92\uff09\u3002\u5b89\u5168\u6027\u65b9\u9762\uff0c\u7279\u745e\u666e\u5229\u5355\u6297\u8054\u5408\u963f\u6614\u66ff\u5c3c\u7684\u5b89\u5168\u6027\u548c\u8010\u53d7\u6027\u826f\u597d\uff0c\u672a\u53d1\u73b0\u65b0\u7684\u5b89\u5168\u6027\u4fe1\u53f7\u3002<\/p>\n\n\n\n \u5317\u4eac\u5927\u5b66\u80bf\u7624\u533b\u9662\u90ed\u519b\u6559\u6388<\/strong>\u8868\u793a\uff1a\u201c\u5728\u5168\u7403\u5c42\u9762\uff0c\u9776\u5411\u8054\u5408\u514d\u75ab\u7597\u6cd5\u5df2\u6210\u4e3a\u665a\u671f\u80be\u764c\u7684\u6807\u51c6\u6cbb\u7597\uff0c\u4f46\u5728\u4e2d\u56fd\u8be5\u9886\u57df\u5c1a\u65e0\u76f8\u5173\u7597\u6cd5\u83b7\u6279\u3002\u6b64\u6b21\u7279\u745e\u666e\u5229\u5355\u6297\u65b0\u9002\u5e94\u75c7\u7684\u83b7\u6279\u5f00\u542f\u4e86\u4e2d\u56fd\u665a\u671f\u80be\u764c\u9776\u514d\u8054\u5408\u7684\u65b0\u7bc7\u7ae0\uff0c\u5c06\u4f1a\u5f7b\u5e95\u6539\u5199\u6211\u56fd\u665a\u671f\u80be\u764c\u7684\u4e34\u5e8a\u5b9e\u8df5\uff0c\u66f4\u91cd\u8981\u7684\u662f\u80fd\u591f\u4e3a\u4e2d\u9ad8\u5371\u60a3\u8005\u5e26\u6765\u65b0\u7684\u6cbb\u7597\u9009\u62e9\uff01\u201d<\/p>\n\n\n\n \u4e0a\u6d77\u4ea4\u901a\u5927\u5b66\u533b\u5b66\u9662\u9644\u5c5e\u4ec1\u6d4e\u533b\u9662\u9ec4\u7ffc\u7136\u6559\u6388<\/strong>\u8868\u793a\uff1a\u201c\u665a\u671f\u80be\u764c\u7684\u6cbb\u7597\u624b\u6bb5\u6709\u9650\uff0c\u7279\u522b\u662f\u4e2d\u9ad8\u5371\u60a3\u8005\u7684\u9884\u540e\u5341\u5206\u4e0d\u7406\u60f3\u3002\u7279\u745e\u666e\u5229\u5355\u6297\u8054\u5408\u963f\u6614\u66ff\u5c3c\u7597\u6cd5\u7684\u83b7\u6279\u586b\u8865\u4e86\u4e2d\u56fd\u4eba\u7fa4\u80be\u764c\u4e00\u7ebf\u514d\u75ab\u6cbb\u7597\u7684\u7a7a\u767d\uff0c\u76f8\u8f83\u9776\u5411\u836f\u5355\u836f\u6cbb\u7597\uff0c\u7279\u745e\u666e\u5229\u5355\u6297\u9776\u514d\u8054\u5408\u7597\u6cd5\u80fd\u591f\u663e\u8457\u63d0\u5347\u60a3\u8005\u7684PFS\uff0c\u5c06\u4e3a\u6211\u56fd\u5e7f\u5927\u665a\u671f\u80be\u764c\u60a3\u8005\u5e26\u6765\u798f\u97f3\u3002\u201d<\/p>\n\n\n\n \u541b\u5b9e\u751f\u7269\u603b\u7ecf\u7406\u517c\u9996\u5e2d\u6267\u884c\u5b98\u90b9\u5efa\u519b\u535a\u58eb<\/strong>\u8868\u793a\uff1a\u201c\u611f\u8c22\u6240\u6709\u53c2\u4e0eRENOTORCH\u7814\u7a76\u7684\u533b\u52a1\u5de5\u4f5c\u8005\u3001\u60a3\u8005\u4ee5\u53ca\u7814\u53d1\u4eba\u5458\u7684\u5949\u732e\uff0c\u8ba9\u4e2d\u56fd\u80be\u764c\u514d\u75ab\u6cbb\u7597\u5b9e\u73b0\u2018\u96f6\u7684\u7a81\u7834\u2019\uff01\u541b\u5b9e\u751f\u7269\u5c06\u7ee7\u7eed\u7acb\u8db3\u4e8e\u56fd\u4eba\u7684\u4e34\u5e8a\u9700\u6c42\uff0c\u6301\u7eed\u6295\u5165\u521b\u65b0\u7814\u53d1\uff0c\u8ba9\u4e2d\u56fd\u60a3\u8005\u83b7\u5f97\u66f4\u597d\u7684\u751f\u5b58\u8d28\u91cf\u548c\u66f4\u957f\u4e45\u7684\u751f\u5b58\u83b7\u76ca\uff01\u201d<\/p>\n\n\n\n <\/p>\n\n\n\n <\/p>\n\n\n\n \u7279\u745e\u666e\u5229\u5355\u6297\u5728\u4e2d\u56fd\u83b7\u6279\u7b2c\u516b\u9879\u9002\u5e94\u75c7<\/p>\n","protected":false},"author":3,"featured_media":2760,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"yoast_head":"\n\u3010\u53c2\u8003\u6587\u732e\u3011<\/h5>\n\n\n\n
1. \u4e2d\u534e\u4eba\u6c11\u5171\u548c\u56fd\u56fd\u5bb6\u536b\u751f\u5065\u5eb7\u59d4\u5458\u4f1a. \u300a\u80be\u7ec6\u80de\u764c\u8bca\u7597\u6307\u5357\uff082022\u5e74\u7248\uff09\u300b. 2022.<\/h5>\n\n\n\n
2. Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl) 2022;135:584-90.<\/h5>\n\n\n\n
3. Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of Renal Cell Carcinoma. World J Oncol 2020;11:79-87.<\/h5>\n\n\n\n
4. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003;30:843-52.<\/h5>\n\n\n\n
5. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27:5794-9.<\/h5>\n\n\n\n
1. \u672c\u6750\u6599\u65e8\u5728\u4f20\u9012\u524d\u6cbf\u4fe1\u606f\uff0c\u65e0\u610f\u5411\u60a8\u505a\u4efb\u4f55\u4ea7\u54c1\u7684\u63a8\u5e7f\uff0c\u4e0d\u4f5c\u4e3a\u4e34\u5e8a\u7528\u836f\u6307\u5bfc\u3002<\/em><\/em><\/h6>\n\n\n\n
2. \u82e5\u60a8\u60f3\u4e86\u89e3\u5177\u4f53\u75be\u75c5\u8bca\u7597\u4fe1\u606f\uff0c\u8bf7\u9075\u4ece\u533b\u7597\u536b\u751f\u4e13\u4e1a\u4eba\u58eb\u7684\u610f\u89c1\u4e0e\u6307\u5bfc\u3002<\/em><\/em><\/h6>\n","protected":false},"excerpt":{"rendered":"